Molecular-targeted nanotherapies in cancer: Enabling treatment specificity

Molecular Oncology

Volumn 5, Issue 6, 2011, Pages 492-503

  Blanco, Elvin ^a   Hsiao, Angela ^a   Ruiz Esparza, Guillermo U ^a   Landry, Matthew G ^a   Meric Bernstam, Funda ^b   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Liposomes; Molecular therapeutics; Nanomedicine; Polymer micelles; SiRNA

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; LIPOSOME; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NANOPARTICLE; NK 012; POLYMER; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; DEGRADATION KINETICS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SPECIFICITY; HUMAN; KAPOSI SARCOMA; MICELLE; MOLECULAR THERAPY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NANOMEDICINE; NANOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 81855198905     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.10.005     Document Type: Review

References (78)

1. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28:3366-3379.
2. Azim H.A., de Azambuja E., Colozza M., Bines J., Piccart M.J. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann. Oncol. 2011, 22:1939-1947.
3. Bey E.A., Bentle M.S., Reinicke K.E., Dong Y., Yang C.R., Girard L., Minna J.D., Bornmann W.G., Gao J., Boothman D.A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc. Natl. Acad. Sci. U S A 2007, 104:11832-11837.
4. Blanco E., Bey E.A., Dong Y., Weinberg B.D., Sutton D.M., Boothman D.A., Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J. Control Release 2007, 122:365-374.
5. Blanco E., Bey E.A., Khemtong C., Yang S.G., Setti-Guthi J., Chen H., Kessinger C.W., Carnevale K.A., Bornmann W.G., Boothman D.A., Gao J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010, 70:3896-3904.
6. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood) 2009, 234:123-131.
7. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am. J. Clin. Oncol. 2010, 33:186-195.
8. Celano M., Schenone S., Cosco D., Navarra M., Puxeddu E., Racanicchi L., Brullo C., Varano E., Alcaro S., Ferretti E., Botta G., Filetti S., Fresta M., Botta M., Russo D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr. Relat. Cancer 2008, 15:499-510.
9. Chiappini C., Tasciotti E., Fakhoury J.R., Fine D., Pullan L., Wang Y.C., Fu L., Liu X., Ferrari M. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem 2010, 11:1029-1035.
10. Ciuffreda L., Del Bufalo D., Desideri M., Di Sanza C., Stoppacciaro A., Ricciardi M.R., Chiaretti S., Tavolaro S., Benassi B., Bellacosa A., Foa R., Tafuri A., Cognetti F., Anichini A., Zupi G., Milella M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009, 11:720-731.
11. Colombo M., Corsi F., Foschi D., Mazzantini E., Mazzucchelli S., Morasso C., Occhipinti E., Polito L., Prosperi D., Ronchi S., Verderio P. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approaches. Pharm. Res. 2010, 62:150-165.
12. Crooke S.T. Progress in antisense technology. Annu. Rev. Med. 2004, 55:61-95.
13. Czeczuga-Semeniuk E., Wolczynski S., Dabrowska M., Dzieciol J., Anchim T. The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. Folia. Histochem. Cytobiol. 2004, 42:221-227.
14. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
15. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
16. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control Release 2010, 141:320-327.
17. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res. 2009, 26:235-243.
18. Dritschilo A., Huang C.H., Rudin C.M., Marshall J., Collins B., Dul J.L., Zhang C., Kumar D., Gokhale P.C., Ahmad A., Ahmad I., Sherman J.W., Kasid U.N. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 2006, 12:1251-1259.
19. Drummond D.C., Noble C.O., Guo Z., Hayes M.E., Connolly-Ingram C., Gabriel B.S., Hann B., Liu B., Park J.W., Hong K., Benz C.C., Marks J.D., Kirpotin D.B. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control Release 2010, 141:13-21.
20. Duenas-Gonzalez A., Garcia-Lopez P., Herrera L.A., Medina-Franco J.L., Gonzalez-Fierro A., Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol. Cancer 2008, 7:82.
21. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, In Press.
22. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
23. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
24. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
25. Ferrari M. Beyond drug delivery. Nat. Nanotechnology 2008, 3:131-132.
26. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010, 28:181-188.
27. Ferrari M. Vectoring siRNA therapeutics into the clinic. Nat. Rev. Clin. Oncol. 2010, 7:485-486.
28. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
29. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharm. 2003, 42:419-436.
30. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19:424-436.
31. Gines J., Sabater E., Martorell C., Grau M., Monroy M., Casado M.A. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin. Transl. Oncol. 2011, 13:485-498.
32. Gnant M. Anticancer activity of bisphosphonates in breast cancer. Anticancer Agents Med. Chem. 2011.
33. Godin B., Gu J., Serda R.E., Bhavane R., Tasciotti E., Chiappini C., Liu X., Tanaka T., Decuzzi P., Ferrari M. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J. Biomed. Mater. Res. A 2010, 94:1236-1243.
34. Gonzalez-Angulo A.M., Hortobagyi G.N., Ellis L.M. Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nat. Rev. Clin. Oncol. 2011, 8:319-320.
35. Grothey A., Ellis L.M. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008, 14:170-177.
36. Hamilton A., Biganzoli L., Coleman R., Mauriac L., Hennebert P., Awada A., Nooij M., Beex L., Piccart M., Van Hoorebeeck I., Bruning P., de Valeriola D. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann. Oncol. 2002, 13:910-918.
37. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
38. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
39. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U S A 2007, 104:5715-5721.
40. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
41. Jin C., Li H., He Y., He M., Bai L., Cao Y., Song W., Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2010, 136:267-274.
42. Kang S.H., Cho H.J., Shim G., Lee S., Kim S.H., Choi H.G., Kim C.W., Oh Y.K. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 2011, In Press.
43. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
44. Kenmotsu H., Yasunaga M., Goto K., Nagano T., Kuroda J., Koga Y., Takahashi A., Nishiwaki Y., Matsumura Y. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 2010, 116:4597-4604.
45. Khong T., Spencer A. Targeting heat shock protein 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol. Cancer Ther. 2011, 10:1909-1917.
46. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
47. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control Release 2008, 129:107-116.
48. Kuesters G.M., Campbell R.B. Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine (Lond) 2010, 5:181-192.
49. Larson N., Greish K., Bauer H., Maeda H., Ghandehari H. Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin. Int. J. Pharm. 2011, 420:111-117.
50. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., Rha S.Y., Lee M.Y., Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108:241-250.
51. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme. Regul. 2001, 41:189-207.
52. Marra M., Salzano G., Leonetti C., Tassone P., Scarsella M., Zappavigna S., Calimeri T., Franco R., Liguori G., Cigliana G., Ascani R., La Rotonda M.I., Abbruzzese A., Tagliaferri P., Caraglia M., De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011, In Press.
53. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
54. Michor F., Liphardt J., Ferrari M., Widom J. What does physics have to do with cancer?. Nat. Rev. Cancer 2011, 11:657-670.
55. Moreira J.N., Simoes S. Technology evaluation: LErafAON, NeoPharm. Curr. Opin. Mol. Ther. 2003, 5:547-552.
56. Morrow P.K., Zambrana F., Esteva F.J. Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 2009, 11:207.
57. Murakami M., Cabral H., Matsumoto Y., Wu S., Kano M.R., Yamori T., Nishiyama N., Kataoka K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 2011, 3. 64ra62.
58. Northfelt D.W., Dezube B.J., Thommes J.A., Levine R., Von Roenn J.H., Dosik G.M., Rios A., Krown S.E., DuMond C., Mamelok R.D. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997, 15:653-659.
59. Nurunnabi M., Cho K.J., Choi J.S., Huh K.M., Lee Y.K. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010, 31:5436-5444.
60. Park J.W., Hong K.L., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
61. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
62. Pegram M.D., Konecny G., Slamon D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 2000, 103:57-75.
63. Petrocca F., Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol. 2011, 29:747-754.
64. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Siegel D., Boothman D.A. NAD(P)H: quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 2000, 275:5416-5424.
65. Ressler S., Mlineritsch B., Greil R. Zoledronic acid for adjuvant use in patients with breast cancer. Expert Rev. Anticancer Ther. 2011, 11:333-349.
66. Richardson P.G., Chanan-Khan A.A., Alsina M., Albitar M., Berman D., Messina M., Mitsiades C.S., Anderson K.C. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br. J. Haematol. 2010, 150:438-445.
67. Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J. Natl. Cancer Inst. 2011, 103:87-89.
68. Serda R.E., Gu J., Bhavane R.C., Liu X., Chiappini C., Decuzzi P., Ferrari M. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials 2009, 30:2440-2448.
69. Smith A.M., Duan H., Mohs A.M., Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 2008, 60:1226-1240.
70. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 2008, 8:473-480.
71. Sutton D., Nasongkla N., Blanco E., Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 2007, 24:1029-1046.
72. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., Han H.D., Shahzad M.M., Liu X., Bhavane R., Gu J., Fakhoury J.R., Chiappini C., Lu C., Matsuo K., Godin B., Stone R.L., Nick A.M., Lopez-Berestein G., Sood A.K., Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70:3687-3696.
73. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., Cheng M.M., Decuzzi P., Tour J.M., Robertson F., Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3:151-157.
74. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
75. Venturini M., Bighin C., Puglisi F., Olmeo N., Aitini E., Colucci G., Garrone O., Paccagnella A., Marini G., Crino L., Mansutti M., Baconnet B., Barbato A., Del Mastro L. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast 2010, 19:333-338.
76. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
77. Zafar S.Y., Malin J.L., Grambow S.C., Abbott D.H., Schrag D., Kolimaga J.T., Zullig L.L., Weeks J.C., Fouad M.N., Ayanian J.Z., Wallace R., Kahn K.L., Ganz P.A., Catalano P., West D.W., Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. BMC Cancer 2011, 11:354.
78. Zhang C., Tang N., Liu X., Liang W., Xu W., Torchilin V.P. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control Release 2006, 112:229-239.